AU2010313273B2 - Methods of treating viral associated diseases - Google Patents

Methods of treating viral associated diseases Download PDF

Info

Publication number
AU2010313273B2
AU2010313273B2 AU2010313273A AU2010313273A AU2010313273B2 AU 2010313273 B2 AU2010313273 B2 AU 2010313273B2 AU 2010313273 A AU2010313273 A AU 2010313273A AU 2010313273 A AU2010313273 A AU 2010313273A AU 2010313273 B2 AU2010313273 B2 AU 2010313273B2
Authority
AU
Australia
Prior art keywords
virus
cells
jcv
dose
bkv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010313273A
Other languages
English (en)
Other versions
AU2010313273A1 (en
Inventor
Ernest Randall Lanier
George R. Painter
Wendy Painter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergent Biodefense Operations Lansing Inc
Original Assignee
Emergent Biodefense Operations Lansing Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Biodefense Operations Lansing Inc filed Critical Emergent Biodefense Operations Lansing Inc
Publication of AU2010313273A1 publication Critical patent/AU2010313273A1/en
Application granted granted Critical
Publication of AU2010313273B2 publication Critical patent/AU2010313273B2/en
Priority to AU2015203573A priority Critical patent/AU2015203573A1/en
Assigned to EMERGENT BIODEFENCE OPERATIONS LANSING LLC reassignment EMERGENT BIODEFENCE OPERATIONS LANSING LLC Request for Assignment Assignors: CHIMERIX, INC.
Assigned to EMERGENT BIODEFENSE OPERATIONS LANSING LLC reassignment EMERGENT BIODEFENSE OPERATIONS LANSING LLC Request to Amend Deed and Register Assignors: EMERGENT BIODEFENCE OPERATIONS LANSING LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010313273A 2009-10-30 2010-10-29 Methods of treating viral associated diseases Active AU2010313273B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015203573A AU2015203573A1 (en) 2009-10-30 2015-06-26 Methods of treating viral associated diseases

Applications Claiming Priority (31)

Application Number Priority Date Filing Date Title
US25670109P 2009-10-30 2009-10-30
US61/256,701 2009-10-30
US32698610P 2010-04-22 2010-04-22
US32698210P 2010-04-22 2010-04-22
US32698910P 2010-04-22 2010-04-22
US32699110P 2010-04-22 2010-04-22
US61/326,991 2010-04-22
US61/326,982 2010-04-22
US61/326,989 2010-04-22
US61/326,986 2010-04-22
US32747410P 2010-04-23 2010-04-23
US61/327,474 2010-04-23
US32791410P 2010-04-26 2010-04-26
US61/327,914 2010-04-26
US32849110P 2010-04-27 2010-04-27
US61/328,491 2010-04-27
US33062410P 2010-05-03 2010-05-03
US61/330,624 2010-05-03
US33170410P 2010-05-05 2010-05-05
US61/331,704 2010-05-05
US35543010P 2010-06-16 2010-06-16
US61/355,430 2010-06-16
US40508410P 2010-10-20 2010-10-20
US40507510P 2010-10-20 2010-10-20
US40507310P 2010-10-20 2010-10-20
US40508010P 2010-10-20 2010-10-20
US61/405,080 2010-10-20
US61/405,073 2010-10-20
US61/405,075 2010-10-20
US61/405,084 2010-10-20
PCT/US2010/054779 WO2011053812A1 (en) 2009-10-30 2010-10-29 Methods of treating viral associated diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015203573A Division AU2015203573A1 (en) 2009-10-30 2015-06-26 Methods of treating viral associated diseases

Publications (2)

Publication Number Publication Date
AU2010313273A1 AU2010313273A1 (en) 2012-05-24
AU2010313273B2 true AU2010313273B2 (en) 2015-04-02

Family

ID=43922582

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010313273A Active AU2010313273B2 (en) 2009-10-30 2010-10-29 Methods of treating viral associated diseases

Country Status (6)

Country Link
US (2) US20130072458A1 (https=)
EP (1) EP2493479A4 (https=)
JP (1) JP2013509433A (https=)
AU (1) AU2010313273B2 (https=)
CA (1) CA2779473C (https=)
WO (1) WO2011053812A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535862A (ja) 2005-04-08 2008-09-04 キメリクス，インコーポレイテッド ポックスウイルス感染の治療のための化合物、組成物および方法
EP2254582B1 (en) 2008-01-25 2016-01-20 Chimerix, Inc. Methods of treating viral infections
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
US9278135B2 (en) 2010-04-26 2016-03-08 Chimerix Inc. Methods of treating retroviral infections and related dosage regimes
ES2604137T3 (es) 2010-08-31 2017-03-03 Chimerix, Inc. Derivados de éster de fosfonato y métodos de síntesis de los mismos
WO2013063436A1 (en) * 2011-10-26 2013-05-02 Chimerix, Inc. Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
ES2874774T3 (es) 2011-12-22 2021-11-05 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
WO2013163509A1 (en) * 2012-04-27 2013-10-31 Chimerix, Inc. A method of mitigating virus associated end-organ damage
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
US9526729B2 (en) * 2013-01-29 2016-12-27 Hsiao Lily Yu Medicament for treating peripheral neuropathies
EA201892769A3 (ru) 2013-03-15 2019-08-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Сложные диэфиры ациклических нуклеозидфосфонатов
DK2999476T3 (en) 2013-11-15 2018-09-03 Chimerix Inc MORPHIC FORMS OF HEXADECYLOXYPROPYL PHOSPHONATE TESTERS
BR112017005111B1 (pt) 2014-09-15 2023-02-14 The Regents Of The University Of California Compostos análogos de nucleotídeo acíclico, composição farmacêutica contendo tais compostos, e usos da composição no tratamento de uma infecção por papilomavírus
EP3212656B1 (en) 2014-10-27 2019-06-05 Concert Pharmaceuticals Inc. Pyrimidine phosphonic acid esters bearing at least one deuterium atom
WO2017048956A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Nucleotide analogs
WO2017196990A1 (en) * 2016-05-12 2017-11-16 Contravir Pharmaceuticals, Inc. Methods of treating hepatitis b infections and related dosage regimes
EP4295853A3 (en) 2016-06-28 2024-03-06 Emergent BioDefense Operations Lansing LLC Formulations of brincidofovir
WO2018156879A1 (en) * 2017-02-23 2018-08-30 Chimerix, Inc. Treatment of adenovirus with brincidofovir
US20220096468A1 (en) * 2018-12-25 2022-03-31 Fujifilm Toyama Chemical Co., Ltd. Therapeutic agent for RNA viral infection comprising a combination of pyrazine derivative and compound which increases amount of pyrazine derivative ribose triphosphate in cell
KR20210145208A (ko) * 2019-03-29 2021-12-01 에보니크 오퍼레이션즈 게엠베하 안토시아닌 조성물 및 항바이러스제를 포함하는 조합 제제
CN117285565A (zh) * 2022-06-24 2023-12-26 润佳（苏州）医药科技有限公司 核苷类似物及其医药用途
IL318465A (en) 2022-07-21 2025-03-01 Antiva Biosciences Inc Compositions and dosage forms for the treatment of HPV infection and HPV-induced neoplasia
JP7417339B1 (ja) 2023-08-07 2024-01-18 シンバイオ製薬株式会社 アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070003516A1 (en) * 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of poxvirus infections

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605602B1 (en) * 2001-09-28 2003-08-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of treating BK virus nephropathy
AU2003231765B9 (en) * 2002-04-26 2010-01-28 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
EP2444071A1 (en) * 2004-09-27 2012-04-25 Sigmoid Pharma Limited Minicapsule formulations
DK2308514T3 (da) * 2007-03-23 2013-09-02 To Bbb Holding B V Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren
WO2008133966A1 (en) * 2007-04-27 2008-11-06 Chimerix, Inc. Methods of reducing nephrotoxicity in subjects administered with nucleoside
WO2011017253A1 (en) * 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
US20110263536A1 (en) * 2010-04-22 2011-10-27 Chimerix, Inc. Methods of Treating Orthopox Virus Infections and Associated Diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070003516A1 (en) * 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of poxvirus infections

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEADLE, JR et al (2002) Antimicrobial Agents and Chemotherapy 46: 2381-6 *
BIDANSET, DJ et al (2004) The Journal of Infectious Diseases 190: 499-503 *
QUENNELLE, DC et al (2007) Antimicrobial Agents and Chemotherapy 51: 4118-4124 *
USFER13504785 *

Also Published As

Publication number Publication date
EP2493479A1 (en) 2012-09-05
JP2013509433A (ja) 2013-03-14
US20130072458A1 (en) 2013-03-21
AU2010313273A1 (en) 2012-05-24
CA2779473A1 (en) 2011-05-05
CA2779473C (en) 2016-08-16
WO2011053812A1 (en) 2011-05-05
EP2493479A4 (en) 2013-04-17
US20150141375A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
AU2010313273B2 (en) Methods of treating viral associated diseases
AU2010279678B2 (en) Composition and methods of treating viral infections and viral induced tumors
US12521397B2 (en) Nucleotide analogs
AU2024205205A1 (en) Methods for treating SARS CoV-2 infections
WO2014124430A1 (en) Nucleotide and nucleoside therapeutic compositions and uses related thereto
AU2015339223A1 (en) Methods for treating Filoviridae virus infections
WO2022046631A1 (en) Phospholipid compounds and uses thereof
KR20230088432A (ko) 인지질 화합물 및 이의 용도
WO2013063436A1 (en) Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
US20170333459A1 (en) Methods of treating orthopox virus infections and associated diseases
US20190085013A1 (en) Nucleotide and nucleoside therapeutic compositions and uses related thereto
JP4545434B2 (ja) 抗ウイルス活性を有する６−‘２−（ホスホノメトキシ）アルコキシピリミジン誘導体
AU2015203573A1 (en) Methods of treating viral associated diseases
CN102665729A (zh) 用于治疗病毒相关性疾病的方法
EP3077403A1 (en) Branched chain acyclic nucleoside phosphonate esters and methods of synthesis and uses thereof
AU2015264949A1 (en) Composition and methods of treating viral infections and viral induced tumors
HK1240226A1 (en) Nucleotide analogs
HK1240226B (en) Nucleotide analogs

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 29 OCT 2021 TO 29 MAR 2023 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 29 MAR 2023

PC Assignment registered

Owner name: EMERGENT BIODEFENCE OPERATIONS LANSING LLC

Free format text: FORMER OWNER(S): CHIMERIX, INC.

HB Alteration of name in register

Owner name: EMERGENT BIODEFENSE OPERATIONS LANSING LLC

Free format text: FORMER NAME(S): EMERGENT BIODEFENCE OPERATIONS LANSING LLC